Recent descriptions of discontinuation syndromes following treatment with antidepressants and antipsychotics, in some cases long lasting, challenge both public and scienti¢c models of addiction and drug dependence. Antipsychotic and antidepressant drug dependencies point to a need to identify predisposing constitutional and personality factors in the patient, pharmacological risk factors in the drug and aspects of therapeutic style that may contribute to the development of stress syndromes. The stress syndromes following antipsychotics also point to the probable existence of a range of syndromes emerging within treatment. The characteristics of these need to be established.
American Psychiatric Association (1990) Task force on benzodiazepine in dependence, benzodiazepine dependence, toxicity and abuse. APA,Washington DC
2.
Antkiewicz-Michaluk L, Karolewicz B, Michaluk J, Vetulani J (1995) Di¡erences between haloperidol and pimozide-induced withdrawal syndrome: a role for Ca2+ channels. Eur J Pharmacol294: 459-467
3.
Battegay R (1967) Drug dependence as a criterion for di¡erentiation of psychotropic drugs. Compr Psychiatry7: 501-509
4.
Bury M, Gabe J (1991) Tranquillisers and health care in crisis. Soc Sci Med32: 449-454
5.
Coupland N J, Bell C J, Potokar J P (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol16: 356-362
6.
Fink M (1998) Electrophysiology and psychopharmacology. In Ban T, Healy D, Shorter E (eds), The rise of psychopharmacology in the 1960s and the story of the CINP. Animula, Budapest
7.
Fitzgerald K, Healy D (1995) Dystonias and dyskinesias of the jaw following the use of SSRIs. Hum Psychopharmacol10: 215-220
8.
Hollister L (1998) From hypertension to psychopharmacology. In Healy D (ed.), The psychopharmacologists II, pp. 215-235. Chapman & Hall, London
9.
Kramer JC, Kline DF, Fink M (1961) Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry118: 549-550
10.
Lane R M (1998) SSRI-induced extrapyramidal side-e¡ects and akathisia: implications for treatment. J Psychopharmacol12: 192-213
11.
Mann A M, MacPherson A S (1959) Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiatric Assoc J4: 38-47
12.
Medawar C (1997) The antidepressant web. Int J Risk Safety Med10: 75-126
13.
Nutt D J (1996) Addiction, brain mechanisms and their treatment implications. Lancet346: 31-36
14.
Oswald I, Lewis SA, Dunleavy D L F, Brezinova V, Briggs M (1971) Drugs of dependence though not of abuse: fen£uramine and imipramine. Brit Med Ji: 70-73
15.
Royal College of Psychiatrists/Royal College of General Practitioners (1992) MORI Poll reveals public confusion about antidepressives and tranquillisers. `Antidepressants not addictive', say Defeat Depression Press Campaign. RCP/RCGP, London
16.
Suppes T, Baldessarini R J, Motohashi N, Tondo L, Viguera AC (1997) Special treatment issues: maintaining and discontinuing psychotropic medications. In Rush A J (ed.), Mood disorders. Systematic medication management. Modern problems in pharmacopsychiatry. Basel, Karger 25: 235-254
Ulett GA, Holden J MC, Itil T M, Keskiner A (1969) A clinical and EEG study of withdrawal syndromes in schizophrenic patients. In Cerletti A, Bove FJ (eds), The present status of psychotropic drugs. Excerpta Medica, Amsterdam
19.
Viguera AC, Baldessarini R J, Hegarty J D, van Kammen DP, Tohen M (1997) Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry54: 49-55
20.
Wegner J T, Struve FA, Kantor J S, Kane J M (1979) Relationship between the B-Mitten EEG pattern and tardive dyskinesia. Arch Gen Psychiatry36: 599-603
21.
WHO Expert Committee on Drug Dependence (1964) 13th Report, WHO Technical Report Series No. 273. World Health Organization, Geneva
22.
WHO Expert Committee on Dependence Producing Drugs (1965) 14th Report,WHO Technical Report Series No. 312.World Health Organization, Geneva
23.
WHO (1992) The International Classi¢cation of Diseases, ICD10. World Health Organization, Geneva
